Abstract 363P
Background
Oral cancer is distressing cancer that affects physically and emotionally and is associated with an adverse impact on mental well-being and financial distress. Informal caregivers are a significant source of support to the patient during and after the treatment of cancer patients. Caregiving may become a burden leading to poor quality of life among caregivers. The study intends to evaluate the effect of a patient's financial distress and psychological well-being on the caregiver's health-related quality of life in early vs advanced oral cancer.
Methods
All oral cancer patients treated with curative intent at our institute from September 2019 to March 2022, with a minimum of 6 months follow-up and disease-free, were included in this study, along with the informal caregivers of the patients. Caretakers not suffering from chronically ill and incurable diseases are included in the study. Patients and caregivers were categorised into early-stage (Group A) and advanced-stage (Group B) based on the clinical staging of patients with oral cancer. The patient's financial distress was evaluated using the COST FACIT questionnaire, and Psychological well-being using DASS 21 questionnaire. The quality of life of the caregivers was evaluated using the WHOQOL BREF questionnaire.
Results
A total of 79 patients and their caregivers were included. The median age is 49 among patients and 38 among caregivers. Twenty-one were in Group A; the rest, fifty-eight, were in Group B. It was observed that the patient in group B has Significant financial distress (p<0.05). There was no difference in HRQOL among caregivers of both groups. There was no correlation between financial distress scores and the caregiver's QOL. There was no effect of the patient's psychological well-being on the QOL of caregivers in group A. However, patients with depression in group B had a significant impact on the caregivers' QOL in the psychological (p <0.05) and environmental domains (p <0.05).
Conclusions
The lack of psychological well-being of patients with advanced-stage cancer significantly influences informal caregivers' psychological and environmental quality of life domains.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract